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Methods and Results: Transthoracic cardioversion was performed 85 * 187 days 
(range 7 minutes to 8 years) after the onset of atrial fibrillation in 315 patients who had a 
mean age of 6lil3 year?,. IRAF was defined as a recurrence of AF within 60 seconds 
after restoration of sinus rhythm. 
Results: IRAF occurred in 56% of patients when cardioversion was performed within 1 
hour of the onset of AF, compared to 12% of patients when cardioversion was performed 
after 24 hours of AF (p<O.OOl). The duration of AF was the only independent predictor of 
IRAF among the clinical variables of age, gender, structural heart disease, antiarrhythmic 
drug therapy, and cardioversion energy (p<O.Ol). 
Conclusions: IRAF is t-mare likely to occur when the duration of AF is cl hour than when 
the duration is ~24 hours. This observation has clinical implications for the most appropri- 
ate timing of cardioversion, particularly in patients who receive device therapy for AF. 
1015-16 Comparison of the Safety and Efficacy of Enoxaparin 
With Unfractionated Heparin and Phenprocoumon as 
Anticoagulation in Cardioversion of Nonvalvular Atrial 
Fibrillation 
Uwe Nixdorff Christoph Stellbhnk. Thomas Hofmann. Peter Hanrath, Walter Lehmacher, 
Andre Schmidt-Lucke. for the ACE Investigators, Medical Clinic II of Erlangen University, 
Erlangen. Germany 
In cardioversion (CV) of atrial fibrillation (AF), anticoagulation with UFH plus oral antico- 
agulant (OAC) is recommended. Conventional CV (OAC for 3 wks before and 4 wks after 
CV) or transesophageal echocardiography (TEE)-guided CV (i.v. UFH infusion plus 4 
wks of OAC, upon exclusion of left atrial (LA) thrombus) can be used. CV using i.v. UFH/ 
OAC is associated with extended hospitalizatton and stringent anticoagulation monitor- 
ing. Therefore LMWH may be a feasible alternative. 
Methods: Patients (n=496) with non-valvular AF lastina 48 h - 1 vear underwent convan- 
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1015-13 Intravenous Amiodarone in Cardioversion of New-Onset 
Atrial Fibrillation 
Jacek Cvbulski, Henryk Danielewicz, Piotr Kulakowski, Andrzej Budaj. Janusz 
Maciejewicz, Teresa Kawka-Urbanek, Leszek Ceremuzynski, Postgraduate Medical 
School, Warszawa. Poland 
Background: Paroxysmal atrial fibrillation (PAF) IS one of the most c~mmcm causes of 
hospital admissron. However, until now, no standard antiarrhythmic therapy has been 
accepted for pharmacological cardioversron of PAF. Amiodarone seems to be a promis- 
ing candidate, but only a few small, randomwad trials are available and the results are 
inconsitent. 
Aim of the study: To assess efficacy of intravenous amiodarone in cardioversion of 
PAF. 
Methods: 160 patients with PAF lasting less than 24 hours were randomly assigned 
(2:1) to amiodarone group (n=l06) receiving 5 mg/kg as a 30 min. iv infusion, followed by 
infusion of 10 mglkg during 20 hours and to the control grup (n=54). Both groups 
received 1000 ml of 10% glucose with 20 IU of rapid action insulin, 60 mEq of potassium 
chloride and 8 g of magnesium sulphate (GIKM) which is electrolyte supplementation 
routinely used in our department rn patients with PAF. Patients requiring emergency DC 
cardioversion were excluded. 
Results: Up to 8 hours after initiation of treatment 53 (50%) patients in amiodarone 
group and 14 (26%) patients in control group were converted to sinus rhythm (~~0.05). 
Twenty hours after initiation of the therapy sinus rhythm was restored in 88 (83%) 
patients in the amiodarone group and in 24 (44%) patients in the control group 
(p<o.oool). 
Conclusion: This study, which is one of the largest ever done on this subject, showed 
that amiodarone is effective in termination of PAF lasting less than 24 hours. It may be 
particularly useful in patients with left ventricular dysfunction, in whom class I antiarrhyth- 
mic agents are contraindicated. 
1015-14 DALTON Study: A Randomized Study Comparing 
Outpatient Dalteparin Administration to Inpatient 
Heparin for the Initiation of Anticoagulation in Atrial 
Fibrillation 
Francois Philippon, Gilles E. CSHara, Jean Champagne, Lyne Charbonneau, Helene 
Villeneuve, Louis Blier, Franck Mokn, Marcel Gilbert, Quebec Heart Institute, Sainte-Fey. 
PQ, Canada 
Atrial fibrillation (AF) patrents who need to be anticoagulated are often admitted to the 
hospital to receive IV heparin until the therapeutic INR has been reached. Some pts are 
sent home on warfarin alone with a potential risk for stroke. We conducted a prospective 
randomized trial compahng ah outpatient strategy using dalteparin (200 I.U./Kg, maxi- 
mum 18 000 I.U.) + warfarin (Da) to standard IV heparin + warfarin (He). A total of 192 
pts were randomized in a B(Da):l(He) ratio and 186 (Da:l42. He:44) completed the study 
(56 women, 130 men). The mean age was 70 * IO yrs and 44 % had a cardiovascular 
history and 50% had hypertension. 47% presented with paroxysmal AF, 50% with persis- 
tent AF and 3% were in chronic AF. The mean EF was 59 f 11% and mean left atrial size 
42 r 7 mm. Sinus rhythm was achieved spontaneously in 64 pts, 18 received ah antiar- 
rhythmic agent and 18 were electrically cardioverted. To achieve proper anticoagulation, 
the He group required a mean of 6.4 + 2.0 days of in-hospital IV heparin and the Da 
group 6.4 21.6 s/c injections. After 21 days, all pts were seen in clinic, 57 were rn AF, 5 in 
atrial flutter, 5 were paced and 119 were in sinus rhythm. Cost-effective and quality of life 
analysis were performed. No major complications or death were observed during the 
study period. Two thromboembotic complications were seen: one in the Da group with a 
pt presenting initially with a TIA the day before randomization (later recognized) and one 
pt in the He group where on day 21 a minor neurological deficit was noticed. Three pts in 
the He group presented with minor hemorrhagic complications (I ecchymosis and 2 
slight Hb drops). In the Da group, 12 pts had small ecchymosis at the injection site, 5 had 
minor epistaxis (one requiring medical anentton without transfusion or hospital admission 
in a pt with concomitant clopidogrel use), 4 had hematomas at the injection site (one 
required medical attention wrthout transfusion while receiving concomitant celecoxib). 
Conclusion: The use of dalteparin for the initiation of anticoagulation in pts with atrial 
fibrillation is a safe alternative to the conventional approach using IV heparin. It offers a 
cost-effective outpatient strategy that can alleviate the need for hospitalization. 
1015-15 Effect of Atrial Fibrillation Duration on Probability of 
Immediate Recurrence After Transthoracic 
Cardioversion 
Hakan Oral Mehmet Ozaydin. Christian Sticherling, Hiroshi Tada, Christoph Scharf, -I 
Aman Chugh, Frank Pelosi, Jr., Bradley P. Knight, Fred Morady, Unwersity of Michigan, 
Ann Arbor, Ml 
Background: An immediate recurrence of atria1 fibrillation (IRAF) appears to be mcwe 
crxnrrwn after early restoratron of sinus rhythm with ah implantable atrial defibrillator than 
after elective transthoracic cardiovenion, suggesting that the probability of IRAF may be 
related to the duration of AF. 
tional (group A, n=65) or TEE-guided CV (group B, n=431). Patients were randomized to 
either the LMWH enoxaoarfn (n=248). or to UFH plus the OAC phenoprocoumon 
(n=248). Patients without TEE:confirmed LA thrombus underwent ‘CV (group 81); 
patients with LA thrombus were anticoagulated for a further 3 wks, and underwent CV if 
repeat TEE did not detect LA thmmbus (group 82). The combined primary efficacy and 
safety endpoint was: stroke, transitory ischemic attacks, systemic embolism, death, and 
major bleeding events. 
Results: In the per-protocol population (n=428). there were no differences in the base- 
line characteristics of the enoxaparin (n=216) and UFH/OAC (n=212) groups. LA thrombi 
were detected in 9.7% of group B (n=370). Mean duration of treatment was 46+/-11 
days, (group A), 29+//-5 days (group Bl), and 46+/-15 days (group 82). Successful CV 
was achieved in 70.8% (303/428 patients): 66.2% (143/216) for enoxaparin and 75.5% 
(1601212) for UFHIOAC, respectively (p=O.O43, explorative). At the end of treatment, 
sinus rhythm was still present in 70.8% (214/303 patients) of successfully cardioverted 
patients: 67.1% (96/143) for enoxaparin and 73.8% (118/160) for UFHIOAC, respectively 
(p=O.21, explorative). Incidence of the primary endpoint was 3.2% (7/216) for enoxaparin 
vs 5.6% (12/212) for UFH/OAC (p=O.O17. confirmatory for equivalence with delta=2%). 
Conclusions: Enoxaparin shows non-inferior efficacy and safety to UFH/OAC in CV of 
AF, and may be preferred due to its reproducibility of anticoagulative effect and mare 
convenient S.C. administration. 
1015-17 Brain Natriuretic Peptide Levels Predict Successful 
Cardioversion and Rhythm Maintenance in Patients 
With Chronic Atrial Fibrillation 
Luis Beck-da-Silva, Adolfo de Bold, Margaret Fraser, Kathryn Williams, Chrrstine 
Struthers, Kayvan Abaiian, Haissam Haddad, University of Ottawa Heart Institute, 
Ottawa, ON, Canada 
Background: Brain natriuretic Peptide (BNP) is released from the heart by hemodynami- 
caky induced muscle stretch. Patients with atrial fibrillation have higher levels of BNP 
than controls in sinus rhythm. The aim of this study is to assess the usefulness of BNP as 
a predictor of successful cardioversion in patients with chronic atrial fibrillation. 
Method?.: We enrolled 20 patients undergoing cardioversion for chronic atrial fibrillation. 
BNP levels were measured prior, 30 min. and two weeks after electric cardioversion. 
Baseline echocardiograms and 12.lead electrocardiogram were obtained from all 
patients. Patients with valvular disease, previous mitral valve surgery or moderate to 
severe left ventricular dysfunction were excluded. 
Results: The mean BNP level and the mean heart rate were significantly higher before 
cardioversion than 30 min after (218 * 176 versus 194 f 196 pglml, p=O.O57; 80 f 22 
versus 56 * 11 pglml, p=O.OOOS) respectively. Patients’ mean ejection fraction was 55 + 
11%. Patients who reverted back to atrial fibrillation after two weeks had baseline BNP of 
260*13 pglml, while those who continued to be in sinus rhythm for two weeks had base- 
line BNP of 149*124 pg/ml, p=O.O27. No correlation was found between left atrial size 
and BNP levels. Left atrial size did not predict successful cardioversion, although most of 
the patients had mild left atrial dilatation (left atrial diameter = 4.6 * 0.6 cm) 
Conclusion: In patients with chronic atrial fibrillation BNP levels may predict successful 
cardioversion and maintenance of sinus rhythm two weeks after cardioversion. 
1015-18 Highly Sensitive C-Reactive Protein Level Predicts 
Recurrence of Atrial Fibrillation After Cardioversion in 
Patients on Antiarrhythmic Drugs 
Oussama Wazni, Nassir F. Marrouche. David Martin, Mostafasahin Shaaraoui, Walid 
Saliba. Eduardo Saad. Mandeeo Bharaava. Aleiandro Perez-Luaones, Andrea Natale, 
The Cleveland Clinic Foundation, Cl&eland, OH 
C-Reactive Protein (CRP) is a sensitive marker of systemtc rnflammation. Chronic eleva- 
tions of baseline CRP is a marker of low level systemic inflammation and has been used 
to predict increased risk for future myocardial infarction and stroke. Recently CRP levels 
